Cancer blood tests include routine blood counts and chemistry tests, selected tumor markers, protein studies, and specialized molecular assays. They can support risk discussions, symptom evaluation, pretreatment baselines, treatment-safety monitoring, response assessment, and follow-up. However, no single blood test can diagnose or rule out most cancers by itself.
Key limitation: A high tumor marker does not automatically mean cancer, and a normal marker does not guarantee that cancer is absent. Benign conditions can raise many markers, some cancers do not release measurable amounts, and the meaning of a result depends on why the test was ordered, the assay used, symptoms, risk factors, imaging, pathology, treatment history, and the trend over time.1, 2
On this page
Start with The Complete Guide to Lab Tests and Blood Work for an overview of specimens, panels, screening, diagnostic support, and monitoring. Use How to Read and Understand Your Lab Results for reference intervals, units, flags, biological variation, and trends. Review Direct-Access Lab Testing: How It Works and What to Expect before ordering, preparing, collecting a specimen, or deciding how to follow up.
Related health-category pillars include:
| Test and quick facts | What it shows and how it is used | Preparation, influences, and limitations |
|---|---|---|
| Complete blood count with differential and platelets Use status: Common or first-line; monitoring | Measures red cells, white cells, platelets, and cell indices. It may help evaluate anemia, infection or marrow patterns, establish a baseline, and monitor treatment effects. | Usually no fasting. Hydration, infection, medicines, altitude, pregnancy, and timing within a treatment cycle can matter. An abnormal CBC is nonspecific, and many cancers cause no CBC change. |
| Comprehensive metabolic panel Use status: Common or first-line; monitoring | Assesses selected kidney, liver, electrolyte, protein, calcium, and glucose measures. It may identify organ effects or support treatment-safety monitoring. | Follow the order-specific fasting instructions. Hydration, medicines, supplements, recent illness, and specimen hemolysis may affect results. A CMP does not locate or diagnose a tumor. |
| PSA and free and total PSA Use status: Risk-based or targeted; monitoring | Supports informed prostate-screening decisions, evaluation of selected prostate concerns, and monitoring after a prostate-cancer diagnosis or treatment. | Prostate enlargement, inflammation, infection, ejaculation, procedures, urinary retention, and some medicines can affect interpretation. No single PSA value proves or excludes cancer. |
| CA-125 Use status: Targeted; monitoring | Most commonly supports monitoring in ovarian cancer and selected evaluation of a suspicious pelvic mass. | Menstruation, pregnancy, endometriosis, fibroids, pelvic inflammation, and liver disease may raise it. It is not recommended as routine screening for average-risk asymptomatic people. |
| CA 15-3 and CA 27.29 Use status: Monitoring; specialist-directed | May be followed in selected people with known breast cancer, especially advanced disease, when the marker is informative for that individual. | Benign conditions and other cancers can affect results, and early or localized breast cancer may not raise them. They do not replace mammography, diagnostic imaging, biopsy, or tumor-tissue biomarker testing. |
| CEA Use status: Monitoring | Provides a pretreatment baseline and may support treatment-response or recurrence monitoring, especially in colorectal cancer. | Smoking and several liver, digestive, inflammatory, or metabolic conditions can raise CEA. It is not a colorectal-cancer screening or diagnostic test by itself. |
| AFP Use status: Targeted; monitoring | May support selected liver-cancer and germ-cell-tumor evaluation, staging context, prognosis, or monitoring. | Pregnancy and chronic liver disease are important confounders. AFP can be elevated without cancer and can remain normal when cancer is present. |
| CA 19-9 and quantitative hCG Use status: Targeted; monitoring | Used in selected pancreaticobiliary, gastrointestinal, trophoblastic, and germ-cell-tumor settings. | Biliary obstruction, pancreatitis, pregnancy, and other clinical circumstances are critical. Neither is a universal cancer-screening test, and some people do not produce CA 19-9. |
| Inhibin A and Inhibin B Use status: Specialist-directed; monitoring | May aid evaluation or monitoring of selected ovarian sex cord-stromal tumors, including granulosa-cell tumors, especially when informative at baseline. | These are not general ovarian-cancer screening tests. Reproductive status, tumor biology, assay method, and specialist context matter. |
| SPEP, serum immunofixation, and free light chains Use status: Targeted; specialist-directed; monitoring | Evaluate a suspected monoclonal protein or plasma-cell disorder and monitor selected known disease. | Inflammation, liver disease, kidney function, medications, and nonmalignant monoclonal gammopathy may affect results. Diagnosis requires a broader clinical workup. |
| Circulating tumor DNA and other liquid-biopsy assays Use status: Specialist-directed, disease-specific, or emerging | Depending on the exact assay, may support treatment selection, molecular residual-disease assessment, a defined disease-specific screening use, or research. | The term covers very different technologies and indications. Regulatory status, validation, intended population, and required diagnostic follow-up must be checked assay by assay. |
Cancer is not one disease, and there is no single blood test that reliably finds every cancer. The phrase cancer blood tests includes several different tools:
A tumor marker may be made by cancer cells or by normal cells responding to cancer or a noncancerous condition. This explains the central limitation: a marker may be high without cancer, and a person may have cancer without a high marker. Results are most useful when the purpose of testing is defined before the blood draw and the interpretation includes symptoms, risk, examination, imaging, pathology, treatment history, and prior values.1, 2
Confusing screening with diagnosis or monitoring can cause harm. Broad testing in people with a low likelihood of disease can produce false-positive results, anxiety, repeat blood draws, imaging, invasive procedures, and cost without a demonstrated improvement in outcomes. A reassuring marker can also create false confidence and delay evaluation of a persistent symptom or abnormal imaging finding.
Focused testing is more useful when it answers a defined question: Is the bone marrow tolerating treatment? Is kidney or liver function changing? Was a marker elevated before treatment, and is the trend consistent with the rest of the clinical picture? Does a person considering PSA screening understand the potential benefits and harms? Is an abnormal protein pattern contributing to unexplained anemia, kidney dysfunction, high total protein, neuropathy, or bone symptoms?
A pretreatment baseline matters when a result will be followed over time. A marker that was never elevated may be a poor monitoring tool for that individual. Trends are also harder to compare when the laboratory, assay method, unit, or clinical circumstances change.
This framework is educational and is not a diagnostic or treatment algorithm.
| Use and status | What the test is being asked to do | What the result cannot do alone |
|---|---|---|
| Population screening Use status: Guideline-defined | Tests people without symptoms to identify who may need diagnostic follow-up. Established examples include mammography, cervical screening, colorectal screening, and low-dose CT for eligible people; PSA requires an informed, individualized decision. | A screening result does not diagnose cancer. Benefit depends on the population, interval, follow-up pathway, and balance of benefits and harms. |
| Risk assessment Use status: Risk-based | Uses family history, exposures, inherited variants, age, and other factors to decide whether surveillance or prevention should change. | Risk information does not show that cancer is currently present. Germline testing and tumor testing answer different questions. |
| Diagnostic support Use status: Targeted | Adds information when symptoms, a mass, abnormal imaging, or another finding is already concerning. CBC, CMP, selected tumor markers, and protein studies may help characterize consequences or narrow next steps. | Blood testing does not replace examination, imaging, endoscopy, bone-marrow evaluation, biopsy, or pathology. |
| Baseline and prognostic context Use status: Specialist-directed | Documents organ function and selected markers before treatment. In defined cancers, a marker may contribute to stage or prognosis when combined with other evidence. | A marker does not determine stage, prognosis, or treatment by itself. |
| Treatment-response monitoring Use status: Monitoring | Follows a previously informative marker and checks blood counts, kidney function, liver function, electrolytes, and other treatment-safety measures. | A falling or rising marker does not prove response or progression without symptoms, examination, imaging, and the oncology plan. |
| Recurrence monitoring Use status: Disease-specific monitoring | Uses serial markers or selected molecular assays after treatment when guidelines or the treating team define a role. | A concerning trend usually prompts confirmation. It does not establish recurrence on its own. |
| Laboratory finding | What it may reveal | What it cannot establish by itself |
|---|---|---|
| Blood-cell counts or cell-index abnormalities | May identify anemia, low platelets, high or low white-cell counts, or other patterns. | Cannot establish the cause. History, repeat testing, smear review, nutritional evaluation, flow cytometry, bone-marrow testing, or other targeted workup may be needed. |
| Organ-function and metabolic abnormalities | May identify changes in liver, kidney, calcium, electrolytes, glucose, or proteins. | Cannot determine whether a solid tumor caused the change or where a tumor is located. Imaging, medication review, and specialist assessment may be needed. |
| A marker above the laboratory interval or a serial change | May signal that a defined follow-up question deserves attention. | Cannot prove cancer, response, progression, or recurrence. Method-consistent repeat testing, imaging, and sometimes biopsy may be required. |
| A monoclonal protein pattern or abnormal free-light-chain ratio | May support evaluation of a plasma-cell or related disorder. | Cannot distinguish MGUS, myeloma, amyloidosis, lymphoma, inflammation, or kidney-related change without additional criteria and evaluation. |
| A tumor-associated genomic alteration | May identify a treatment-associated biomarker in a validated setting. | Cannot guarantee that a therapy will work or that tissue testing is unnecessary. |
| A cancer signal on a disease-specific or multi-cancer assay | May identify a need for a coordinated diagnostic workup. | Cannot serve as pathology or establish the exact cancer site with certainty. A negative result does not exclude cancer. |
A hormone-sensitive cancer depends in part on hormonal signaling for growth. A hormone-producing tumor may release hormones or related substances. These categories overlap in some cases, but they are not the same. Most importantly, neither term means that a routine hormone blood test can find the tumor.
In breast cancer, estrogen-receptor and progesterone-receptor status is generally determined by testing tumor tissue obtained during a biopsy or surgery. Serum estrogen or progesterone levels do not establish whether a tumor is ER-positive or PR-positive.3 In prostate cancer, androgen signaling can influence treatment, but a circulating testosterone result is not a prostate-cancer screening or diagnostic test.
Traditional tumor markers may still support selected monitoring questions. CA 15-3 and CA 27.29 may be followed in selected people with known breast cancer, while Inhibin A or Inhibin B may be used in selected ovarian sex cord-stromal-tumor settings. These uses are targeted and specialist-directed; they do not create a stand-alone early-detection pathway.2, 15
| Test or concept and use status | How it may be used | Critical limitation |
|---|---|---|
| ER, PR, HER2, and other tumor-tissue biomarkers Use status: Specialist-directed tissue testing | Breast-cancer cells are commonly tested after biopsy or surgery to determine receptor and biomarker status and help plan treatment.3 | These are not routine serum hormone measurements. A blood estrogen or progesterone result does not establish whether a breast tumor is ER-positive or PR-positive. |
| Circulating estrogen or progesterone Use status: Selected endocrine or treatment context | May be measured for defined endocrine questions or in selected treatment-monitoring situations directed by the treating team. | Does not screen for breast cancer, diagnose a hormone-sensitive tumor, or substitute for receptor testing on tumor tissue. |
| CA 15-3 Use status: Monitoring; specialist-directed | May be followed in selected people with known breast cancer, particularly advanced disease, when it is informative for that individual.2 | Not a breast-cancer screening or diagnostic test. A normal result does not rule out disease, and a change must be interpreted with imaging and the treatment plan. |
| CA 27.29 Use status: Monitoring; specialist-directed | May support selected breast-cancer follow-up or monitoring when a baseline and clinical indication exist.2 | Does not replace mammography, diagnostic breast imaging, biopsy, or pathology. Benign conditions and other cancers may affect the result. |
| PSA and selected total testosterone monitoring Use status: Risk-based or oncology-directed | PSA may support informed screening decisions and prostate-cancer monitoring. Testosterone may be monitored during selected androgen-deprivation treatment plans.4 | Androgen dependence does not make testosterone a prostate-cancer detection test. PSA and testosterone trends must be interpreted with treatment history, symptoms, examination, and imaging. |
| Inhibin A and Inhibin B Use status: Specialist-directed; monitoring | May aid evaluation or follow-up of selected ovarian sex cord-stromal tumors, including granulosa-cell tumors, particularly when a marker was informative at diagnosis.15 | Not general ovarian-cancer screening tests. Reproductive status, menopause, tumor biology, assay method, and the specialist-defined purpose of testing matter. |
| Scenario and urgency | Laboratory tests that may add information | Nonlaboratory evaluation and limitations |
|---|---|---|
| Persistent fatigue, pallor, bruising, infections, or unexplained weight loss Urgency: Prompt review if persistent; urgent for severe weakness, uncontrolled bleeding, or fever during cancer treatment | CBC with differential and CMP may assess blood-cell and organ-function patterns. Additional anemia or hematology testing should be selected from the findings. | These symptoms have many noncancer causes. History, examination, repeat testing, imaging, or hematology evaluation may be needed. |
| Visible blood in urine, stool, sputum, or vomit; unexplained vaginal bleeding Urgency: Heavy bleeding, fainting, black stool, or coughing or vomiting blood may be an emergency | CBC, CMP, and complete urinalysis may assess consequences or alternative explanations. | Do not substitute a tumor marker for prompt urologic, gastrointestinal, gynecologic, pulmonary, imaging, or endoscopic evaluation. |
| New mass, enlarging lymph node, persistent focal pain, or nonhealing lesion Urgency: Arrange prompt examination | CBC, CMP, and selected context-specific tests may add information. | Physical examination, ultrasound or other imaging, and biopsy may be required. Do not delay evaluation while waiting for a tumor-marker result. |
| Jaundice, dark urine, pale stool, or persistent upper-abdominal pain Urgency: Fever with jaundice, confusion, severe pain, or persistent vomiting requires urgent assessment | CMP can assess liver and metabolic patterns. CA 19-9 belongs only in a defined professional pancreaticobiliary workup. | Gallstones, hepatitis, pancreatitis, medication injury, obstruction, and malignancy are among many possibilities. Imaging and gastroenterology or emergency evaluation may be needed. |
| Urinary obstruction, blood in urine or semen, pelvic or back pain, or a prostate-screening decision Urgency: Urinary retention, fever with urinary symptoms, or severe pain needs prompt care | Urinalysis, total PSA, and sometimes free and total PSA may add information after clinical review. | Benign prostate enlargement, prostatitis, infection, and stones can cause similar findings. Examination, urology review, MRI, cystoscopy, or biopsy may be indicated. |
| Persistent bloating, pelvic pressure, early satiety, or a pelvic mass Urgency: Severe pain, fainting, acute bleeding, or pregnancy concerns require urgent evaluation | CBC, CMP, and selected CA-125 testing may support a risk-informed evaluation. | Pelvic examination and ultrasound are central. CA-125 cannot diagnose ovarian cancer and is not routine screening for average-risk asymptomatic people. |
| Unexplained anemia, kidney dysfunction, high total protein, bone pain, neuropathy, or recurrent fractures Urgency: New weakness, spinal-cord symptoms, severe hypercalcemia symptoms, or acute kidney injury requires urgent care | CBC, CMP, SPEP, serum immunofixation, free light chains, and related testing may be considered. | Imaging, urine protein studies, bone-marrow evaluation, nephrology, neurology, or hematology review may be needed. An abnormal protein test is not automatically myeloma. |
| Strong family history, early-onset cancers, multiple primary cancers, or a known familial variant Urgency: Nonurgent unless symptoms are present, but planning should not be delayed indefinitely | Germline testing selected with genetic counseling may be appropriate. See Genetic and Genomic Testing. | Hereditary risk testing does not diagnose a current cancer. A negative limited panel does not erase a strong family history. |
CBC, CMP, urinalysis, and other symptom-directed tests often assess blood-cell patterns, organ effects, metabolic changes, or treatment safety. They are not cancer panels and cannot exclude malignancy.
PSA, free and total PSA, CA-125, AFP, CA 19-9, quantitative hCG, CA 15-3, CA 27.29, Inhibin A, Inhibin B, LDH, SPEP, immunofixation, and free light chains may be useful when symptoms, history, imaging, a confirmed diagnosis, or a specialist-defined question provides a reason to order them.
Serial tumor markers can be useful when a marker is validated for the cancer type and was informative for the individual. CBC and CMP commonly support monitoring of marrow, kidney, liver, electrolyte, and metabolic effects of treatment. A marker trend should be interpreted with symptoms, examination, imaging, pathology, and the oncology plan.
Tumor genomic profiling, plasma companion diagnostics, molecular residual-disease assays, complex hematologic testing, and some hereditary cancer panels require disease-specific selection and interpretation.
Multi-cancer detection tests remain an evolving category. Detecting a signal is not the same as proving that population use reduces cancer mortality or produces more benefit than harm. A positive result requires a coordinated diagnostic pathway, and a negative result does not replace established screening or symptom evaluation.19, 20
In average-risk, asymptomatic people, broad bundles of CA-125, CEA, AFP, CA 19-9, hCG, LDH, CA 15-3, CA 27.29, inhibins, and similar markers are generally not supported as universal cancer screening. The chance of false-positive, incidental, or uninterpretable findings rises when many nonspecific tests are ordered without a defined pretest question.
| Test and quick facts | What it shows and how it is used | Preparation, influences, and limitations |
|---|---|---|
| Complete Blood Count with Differential and Platelets Aliases: CBC, CBC with differential Use status: Common or first-line; monitoring | Measures red-cell, white-cell, and platelet counts and indices. May evaluate anemia, infection or marrow patterns, establish a baseline, and monitor treatment effects. | Usually no fasting. Hydration, recent illness, steroids, treatment timing, altitude, pregnancy, and specimen quality may matter. It cannot identify the cause of an abnormal count or exclude cancer. |
| Comprehensive Metabolic Panel Alias: CMP Use status: Common or first-line; monitoring | Measures selected kidney, liver, electrolyte, protein, calcium, and glucose values. May assess organ function, metabolic effects, and treatment safety. | Follow the order-specific fasting instructions. Hydration, medicines, supplements, illness, and hemolysis may affect results. It cannot establish a tumor's presence, location, type, or stage. |
| Complete Urinalysis Alias: UA Use status: Common or symptom-directed | Assesses urine blood, protein, glucose, cells, and other features. May help evaluate visible or microscopic blood in urine and alternative urinary causes. | Collection quality, menstruation, exercise, hydration, infection, stones, and medications can affect findings. Urinalysis cannot diagnose or exclude bladder, kidney, or prostate cancer. |
| Lactate Dehydrogenase Aliases: LDH, LD Use status: Targeted; monitoring; specialist-directed | Measures an enzyme released with tissue and cell injury. May contribute to prognosis or monitoring in selected lymphomas, germ-cell tumors, and other defined settings. | Hemolysis, exercise, liver or muscle injury, infection, inflammation, and medicines may raise LDH. It does not identify cancer, site, or recurrence by itself. |
| Serum Protein Electrophoresis Alias: SPEP Use status: Targeted; specialist-directed; monitoring | Shows the distribution of serum protein fractions and may reveal a monoclonal pattern. Used in selected evaluation of high total protein, anemia, kidney dysfunction, bone symptoms, or neuropathy. | Usually no fasting. Inflammation, liver disease, protein loss, immunoglobulin therapy, and specimen factors matter. It cannot diagnose multiple myeloma or another specific disorder alone. |
| Serum Immunofixation Alias: IFE Use status: Targeted; specialist-directed; monitoring | Characterizes the type of monoclonal immunoglobulin or light chain when present and may follow an abnormal SPEP. | Recent monoclonal-antibody treatment, immunoglobulin administration, and method can affect interpretation. A detected monoclonal protein may occur in MGUS or other nonmalignant states. |
| Kappa/Lambda Free Light Chains with Ratio Aliases: FLC, sFLC Use status: Targeted; specialist-directed; monitoring | Measures free kappa and lambda light chains and their ratio. Complements SPEP and IFE in selected plasma-cell-disorder evaluation and monitoring. | Kidney function, inflammation, assay platform, and treatment matter. It cannot establish the exact disorder, organ involvement, or need for treatment by itself. |
| Beta-2 Microglobulin, Serum Alias: B2M Use status: Specialist-directed; prognostic or monitoring | Measures a small protein influenced by cell turnover and kidney filtration. May contribute to prognosis or monitoring in multiple myeloma, chronic lymphocytic leukemia, and some lymphomas. | Kidney dysfunction, inflammation, infection, and immune activation can raise it. It is not a cancer-screening or diagnostic test. |
| Marker and quick facts | What it shows and how it is used | Preparation, influences, and limitations |
|---|---|---|
| PSA, Total Aliases: total PSA, prostate-specific antigen Use status: Risk-based or targeted; monitoring | May support individualized prostate-screening decisions, symptom evaluation, pretreatment baseline, and monitoring after diagnosis or treatment.4, 5 | Benign enlargement, prostatitis, infection, ejaculation, procedures, urinary retention, and some medicines affect interpretation. No single value proves or excludes cancer. |
| PSA, Free and Total Aliases: percent free PSA, free-to-total PSA ratio Use status: Targeted adjunct | May refine risk discussion in selected people with an elevated or borderline total PSA. | Interpret with total PSA, age, trend, prostate volume, examination, risk, and imaging. No percentage excludes clinically significant disease. |
| Post-Prostatectomy PSA Use status: Monitoring after prostatectomy | Uses a sensitive PSA method in the defined post-prostatectomy setting to follow the treating team's monitoring plan. | A single result should not be interpreted without timing, assay, prior values, pathology, and the oncology or urology plan. |
| CA-125 Aliases: cancer antigen 125, ovarian cancer antigen Use status: Targeted; monitoring | Most commonly monitors known ovarian cancer and may contribute to selected evaluation of a suspicious pelvic mass.7 | Menstruation, pregnancy, endometriosis, fibroids, pelvic inflammation, and liver disease may raise it. It is not routine screening for average-risk asymptomatic people. |
| CA 15-3 Use status: Monitoring; specialist-directed | May help assess treatment response or recurrence in selected breast-cancer settings when informative for the individual.2 | Not a breast-cancer screening or diagnostic test. Benign conditions and other cancers may affect it; early disease may not raise it. |
| CA 27.29 Use status: Monitoring; specialist-directed | May be followed in selected people with known breast cancer, particularly for metastatic or recurrence monitoring questions.2 | Does not replace mammography, diagnostic imaging, biopsy, pathology, or receptor testing. Interpret serially with the same method when possible. |
| Carcinoembryonic Antigen Alias: CEA Use status: Monitoring | Commonly provides a baseline and supports treatment-response or recurrence monitoring in colorectal cancer and selected other cancers.8 | Smoking and several liver, digestive, inflammatory, and metabolic conditions may raise CEA. It is not a colorectal-cancer screening or diagnostic test. |
| Alpha-Fetoprotein Tumor Marker Alias: AFP Use status: Targeted; monitoring | May contribute to selected liver-cancer and germ-cell-tumor evaluation, staging context, prognosis, and response monitoring.2, 9 | Pregnancy and chronic liver disease materially affect interpretation. AFP may be elevated without cancer or normal despite cancer. |
| CA 19-9 Use status: Targeted; monitoring | May support treatment-response monitoring in pancreatic, biliary, gallbladder, gastric, and selected related cancers.2, 10 | Biliary obstruction, cholangitis, pancreatitis, and other benign conditions can raise it. Some people do not produce CA 19-9. It is not population screening. |
| hCG, Total, Quantitative Aliases: beta-hCG, quantitative hCG Use status: Targeted; monitoring | May contribute to staging, prognosis, and monitoring in selected germ-cell and trophoblastic tumors.2 | Pregnancy is the central alternative explanation. Pituitary production, assay interference, and other rare causes may matter. It is not a universal screening marker. |
| Inhibin A Use status: Specialist-directed; monitoring | May be used with clinical findings and imaging in selected ovarian sex cord-stromal or granulosa-cell-tumor evaluation and follow-up.15 | Not a general ovarian-cancer screening test. Reproductive and menopausal status, tumor type, baseline result, and assay method matter. |
| Inhibin B Use status: Specialist-directed; monitoring | May be particularly useful in selected granulosa-cell-tumor follow-up when elevated or informative at diagnosis.15 | Not a stand-alone diagnostic or screening test. A normal result does not exclude disease, and performance varies by tumor and assay. |
| Cancer type | Screening or risk-directed pathway | What a tumor marker cannot replace |
|---|---|---|
| Breast cancer | Use guideline-based mammography and any risk-directed imaging or genetic evaluation. Tumor-tissue biomarkers guide treatment after diagnosis.22 | CA 15-3, CA 27.29, serum estrogen, and serum progesterone do not replace breast screening, diagnostic imaging, biopsy, or tissue receptor testing.3, 21 |
| Cervical cancer | Use current cervical screening recommendations and appropriate diagnostic follow-up for an abnormal result.23 | There is no routine circulating tumor marker that substitutes for cervical screening. |
| Colorectal cancer | Use established stool-based tests, colonoscopy, or another guideline-recognized option. An FDA-approved blood-based screening test is available for defined average-risk adults; a positive result requires colonoscopy.24, 16 | CEA is primarily a monitoring marker and is not a substitute for colorectal screening or diagnostic colonoscopy. |
| Lung cancer | Use low-dose CT for people who meet current eligibility criteria. Evaluate symptoms such as persistent cough or coughing blood promptly.25 | No routine blood tumor marker replaces low-dose CT or diagnostic chest imaging. |
| Prostate cancer | Consider PSA only through an informed, individualized decision that accounts for age, health, risk, preferences, potential follow-up, and possible harms.4, 5 | PSA is not cancer-specific. A high value does not diagnose cancer, and a low value does not completely exclude it. |
| Ovarian cancer | Average-risk asymptomatic people should not use CA-125 as routine population screening. High-risk care requires individualized specialist guidance. | CA-125, Inhibin A, and Inhibin B are not universal ovarian-cancer screening tests.6, 7 |
| Pancreatic cancer | Average-risk asymptomatic adults should not undergo population screening. High-risk surveillance programs use specialist-defined protocols.26 | CA 19-9 cannot screen the general population or distinguish cancer from biliary obstruction or pancreatitis by itself. |
| Liver cancer | People at defined high risk may need specialist-directed surveillance using imaging and, in some protocols, AFP. | AFP alone cannot screen everyone, diagnose liver cancer, or exclude disease. Chronic liver disease and pregnancy can affect it. |
Liquid biopsy is an umbrella term, not one test. Some assays analyze circulating tumor DNA or other material to select treatment for an already diagnosed cancer. Others assess molecular residual disease after treatment. A disease-specific blood screening test may have a defined regulatory indication. Multi-cancer detection assays ask a broader screening question and remain under active study.
Always identify the exact assay, intended population, regulatory status, specimen, cancer type, decision it is meant to support, and required follow-up. A result from one category should not be generalized to another.17, 18, 19
| Assay category and status | Defined use | Critical limitation |
|---|---|---|
| Plasma companion diagnostic Use status: FDA-authorized, treatment-specific | Looks for a defined alteration linked to a specific drug indication. FDA maintains a list of authorized companion diagnostic devices.17 | Use is limited to the assay, cancer type, specimen, and treatment described in the authorization or labeling. It is not general cancer screening. |
| Molecular residual-disease assay Use status: Disease-specific and rapidly evolving | Looks for a molecular signal after treatment. In May 2026, FDA approved Signatera CDx as a companion diagnostic in a defined post-cystectomy muscle-invasive bladder-cancer setting for adjuvant atezolizumab selection.18 | That approval does not establish the same role for every MRD assay, cancer, treatment, or surveillance schedule. A negative result is not a universal all-clear. |
| Disease-specific blood screening Use status: FDA-approved for a defined population | The Shield blood test is approved for colorectal-cancer screening in average-risk adults age 45 or older. A positive result should be followed by colonoscopy.16 | It is not a replacement for diagnostic colonoscopy or surveillance colonoscopy in high-risk people. A screening option must be chosen with attention to performance, adherence, and required follow-up. |
| Multi-cancer detection test Use status: Emerging or research-oriented for population outcomes | Analyzes one or more signals to look for multiple cancers. NCI notes that definitive evidence of reduced overall cancer mortality is not yet available, and benefits and harms remain under study.19 | A positive signal starts a diagnostic process rather than establishing cancer. A negative result does not replace proven screening. The NHS-Galleri trial did not meet its primary endpoint of reducing late-stage diagnoses, although other stage-distribution findings continue to be studied.20 |
| Order type | When it may fit | Main limitation |
|---|---|---|
| Individual test | Best when one defined question points to one marker or one foundational test. | Usually easier to interpret and less likely to generate unrelated abnormalities, but may be incomplete if the clinical question requires a coordinated set of tests. |
| Focused panel or profile | Best when several complementary measurements answer one clinical question, such as CBC indices or protein studies. | Panel contents must be reviewed. A coherent panel is not automatically a cancer-screening panel. |
| Broad multi-marker panel | May be appropriate only in a defined specialist or research context with a planned follow-up pathway. | In average-risk asymptomatic people, many nonspecific markers can increase false positives, incidental findings, anxiety, and unnecessary procedures without proven benefit. |
| Test or test group | Preparation and timing | Influences and limitations |
|---|---|---|
| CBC, CMP, and treatment-safety testing | Follow the specific order instructions. Fasting may be requested when glucose or other fasting-sensitive tests are included. Keep hydration and treatment-cycle timing consistent when possible. | Dehydration, infection, steroids, treatment timing, supplements, medicines, and specimen hemolysis may change results. Do not stop medicines without professional instruction. |
| PSA and free PSA | Document recent prostate infection, urinary retention, procedures, biopsy, catheterization, ejaculation, and relevant medicines. Follow the ordering clinician's timing instructions. | A temporary rise may reflect a noncancer prostate influence. A repeat may be appropriate, but persistent symptoms or concerning examination findings still need evaluation. |
| CEA | Usually no fasting. Record smoking status and relevant liver, digestive, inflammatory, or metabolic conditions. | Smoking and noncancerous disease may raise the result. The same assay is preferable for serial comparison. |
| CA-125, Inhibin A, and Inhibin B | Document pregnancy possibility, menstrual or menopausal status, pelvic conditions, surgery, and the exact reason for testing. | Reproductive physiology and benign pelvic or liver conditions can affect interpretation. These tests do not replace pelvic imaging or pathology. |
| AFP and quantitative hCG | Document pregnancy status and relevant liver or germ-cell-tumor history. Use the same method for serial monitoring when possible. | Pregnancy is a major confounder. Chronic liver disease can raise AFP. Assay interference and clinical context may matter for hCG. |
| CA 19-9 | Document jaundice, biliary obstruction, cholangitis, pancreatitis, and recent procedures or treatment. | Obstruction and inflammation can cause marked elevations, and some people do not produce CA 19-9. |
| SPEP, immunofixation, and free light chains | Usually no fasting. Provide kidney function, inflammatory status, recent immunoglobulin administration, and monoclonal-antibody treatment history. | Kidney dysfunction and inflammation may alter free-light-chain concentrations. Therapy can create patterns that complicate electrophoresis or immunofixation. |
Use How to Read and Understand Your Lab Results for a fuller explanation of reference intervals, decision thresholds, flags, units, biological variation, analytical variation, repeat testing, and trends.
| Report term | What it means | What it does not mean |
|---|---|---|
| Reference interval | The range or decision information supplied by the performing laboratory for that method and population. | It is not a universal boundary between cancer and no cancer. |
| Flag | A notation that a value is outside the laboratory interval or decision limit. | A high or low flag does not identify the cause or determine urgency by itself. |
| Unit and method | The measurement unit and assay platform used by the laboratory. | Results from different methods may not be directly interchangeable. |
| Baseline | A result obtained before treatment or before serial monitoring begins. | A marker that was never elevated may not be useful for monitoring that individual. |
| Trend | The direction and magnitude of change across comparable measurements. | A trend must be interpreted with timing, treatment, symptoms, imaging, and biological and analytical variation. |
| Discordant result | A laboratory result that does not fit symptoms, imaging, pathology, or the rest of the data. | Discordance is a reason to verify the test and context, not to ignore either the laboratory result or the clinical picture. |
Educational example only: The patient, values, and circumstances below are fictional. No universal reference interval is implied.
| Report element | Fictional entry or question | Interpretation limit |
|---|---|---|
| Test CEA | Was it ordered to monitor a known CEA-producing cancer or as unspecific screening? | The indication determines the pretest probability and the appropriate next step. |
| Value and unit Mildly above the laboratory interval in ng/mL | What exact method and interval were used? Was the same assay used previously? | A mild elevation is not a diagnosis. |
| Flag H | The result is above the laboratory interval. | The flag does not identify cancer or the cause of the elevation. |
| Prior result No prior CEA available | Without a baseline, a trend cannot be assessed. | One value cannot show whether the marker is rising, stable, or falling. |
| Related results CBC without a major abnormality; mild liver-enzyme elevation on CMP | Could liver, digestive, inflammatory, metabolic, medication, or smoking factors contribute? | Normal related tests do not exclude cancer, and abnormal related tests do not prove it. |
| History and preparation Smoking status, recent illness, and reason for ordering not documented | These missing details materially limit interpretation. | A result should not be interpreted without the clinical context that could explain it. |
| Possible follow-up | Review indication and symptoms, assess benign contributors, confirm only when appropriate, and use guideline-based colorectal screening or targeted diagnostic evaluation. | CEA should not be used to diagnose or exclude colorectal cancer. |
Repeat testing can be useful when a specimen problem, acute illness, procedure, timing issue, medication, or known biological variation could explain an unexpected result. The repeat should generally use the same method and laboratory when a trend is the goal. The reason for the repeat, timing, and action threshold should be clear.
Confirmatory testing means more than drawing the same marker again. Depending on the question, confirmation may require a different laboratory method, imaging, endoscopy, pathology, tumor-tissue biomarker testing, bone-marrow evaluation, or specialist assessment. Repeating a marker indefinitely without a defined plan can prolong uncertainty without answering the clinical question.
Seek prompt professional evaluation for a new mass, persistent unexplained bleeding, progressive jaundice, blood in urine, worsening neurologic symptoms, unexplained weight loss, persistent focal pain, or symptoms that do not resolve. Contact the oncology team promptly for fever during treatment, rapidly worsening weakness, new bleeding, severe vomiting, dehydration, or unexpected treatment-related symptoms.
Emergency evaluation may be necessary for uncontrolled bleeding, fainting, severe shortness of breath, coughing or vomiting blood, black tarry stool, urinary retention with severe pain or fever, jaundice with confusion or fever, new weakness or loss of bladder or bowel control, or other rapidly progressive symptoms. A laboratory order should never delay emergency care.
The following links lead to individual Ulta Lab Tests pages. Availability and suitability depend on the purpose of testing. A direct-access order does not diagnose cancer or replace established screening, imaging, pathology, or oncology care.
Browse the Ulta Lab Tests tumor-marker category only after defining the purpose of testing. A larger panel is not automatically a better screening strategy.
Ulta Lab Tests provides access to many of the individual laboratory tests discussed in this guide. Direct-access testing can make it easier to obtain a defined baseline or follow a clinician-directed plan, but ordering access does not change a test's medical limitations.
Before ordering, confirm the purpose, preparation, timing, and follow-up plan. Review Direct-Access Lab Testing: How It Works and What to Expect for the ordering and collection process, and use How to Read and Understand Your Lab Results when reviewing the report. Persistent symptoms, marked abnormalities, or cancer-treatment decisions require qualified professional care.
Usually not by itself. Blood tests may reveal patterns, measure selected tumor markers, or identify a molecular signal, but most cancer diagnoses require imaging, endoscopy, biopsy, pathology, or another disease-specific confirmation.
No. Some cancers do not produce the marker, early disease may produce little of it, and individual biology varies. Persistent symptoms or an abnormal examination or imaging finding still require evaluation.
No. Benign conditions can raise many markers. The test, unit, method, reason for ordering, prior values, symptoms, and related findings must be reviewed before choosing follow-up.
Examples include PSA in prostate cancer, CEA in colorectal cancer, CA-125 in ovarian cancer, AFP and hCG in selected germ-cell tumors, CA 19-9 in selected pancreaticobiliary cancers, CA 15-3 or CA 27.29 in selected breast-cancer settings, and Inhibin A or Inhibin B in selected ovarian sex cord-stromal tumors. The exact role depends on the cancer, baseline result, treatment, and guideline or specialist plan.
PSA is prostate-associated, not cancer-specific. It may support an informed screening decision, evaluation of selected prostate concerns, or monitoring after diagnosis or treatment. Benign enlargement, inflammation, infection, procedures, and medicines may affect the result.
It is not recommended as routine population screening for average-risk asymptomatic people. It is used mainly to monitor known ovarian cancer and may contribute to evaluation of a suspicious pelvic mass or a specialist-directed high-risk plan.
No. A blood hormone concentration does not determine whether a tumor contains estrogen or progesterone receptors. In breast cancer, receptor status is generally tested directly on tumor tissue obtained during biopsy or surgery. Serum hormone testing may have selected endocrine or treatment-monitoring uses, but it does not replace screening, diagnostic imaging, biopsy, or tumor-tissue biomarker testing.
They should not be used as stand-alone early-detection or screening tests. They may support monitoring in selected people with known breast cancer, particularly advanced disease, when the marker is informative for that individual.
They may aid specialist-directed evaluation or monitoring of selected ovarian sex cord-stromal tumors, including granulosa-cell tumors. They are not general ovarian-cancer screening tests, and interpretation depends on reproductive status, tumor biology, baseline values, assay method, imaging, and pathology.
They assess blood-cell and organ-function patterns that may support symptom evaluation, establish baselines, and monitor treatment safety. They are nonspecific and cannot locate or diagnose a tumor.
No. Some liquid biopsies are companion diagnostics for treatment selection, some assess molecular residual disease, some have a defined disease-specific screening indication, and others are emerging multi-cancer detection tests. The exact assay and intended use must be checked.
Definitive evidence that population use reduces overall cancer mortality is not yet available. Trials are evaluating benefits, harms, stage distribution, diagnostic workups, and mortality. These tests do not replace established screening.
Hereditary testing looks for germline variants that may affect inherited risk and relatives. Tumor-marker testing usually measures a circulating protein or disease signal. Tumor genomic testing examines acquired changes in cancer cells and may guide treatment. These tests answer different questions.
Not automatically. Larger panels can generate incidental abnormalities, false reassurance, anxiety, and follow-up procedures without improving screening. A focused test linked to a defined clinical question is usually easier to interpret.
Cancer blood tests include routine blood counts and chemistry testing, selected tumor markers, monoclonal-protein studies, and increasingly specialized molecular assays. Focused testing can support risk discussions, diagnostic evaluation, treatment safety, response assessment, and recurrence monitoring. It cannot by itself diagnose most cancers, rule cancer out, or replace established screening, imaging, endoscopy, biopsy, pathology, and specialist evaluation.
The safest approach begins with the purpose of testing, weighs false-positive and false-negative consequences, and interprets each result in the context of symptoms, risk, preparation, method, related findings, and trends. For hormone-sensitive cancers, keep tissue receptor testing, circulating hormone measurements, and traditional tumor markers conceptually separate. CA 15-3, CA 27.29, Inhibin A, and Inhibin B have selected monitoring roles; they are not stand-alone early-detection tests.
Ulta Lab Tests offers laboratory-testing services and links to individual tests discussed on this page. This educational content does not provide an individual diagnosis or treatment plan. Cancer screening, diagnostic evaluation, treatment, and surveillance should follow current guidelines and the plan established with qualified health professionals.
Written by: John R. | Originally published: August 1, 2026 | Last updated: August 11, 2026
Medical note: This guide is educational. A clinician should select and interpret testing in the context of symptoms, diagnoses, medications, pregnancy status, nutrition, hydration, and prior results. Do not start, stop, or change a prescription based on this article or one laboratory result.
These tests provide blood-cell, liver, kidney, electrolyte, protein, glucose, and treatment-safety context. They are not cancer-specific tests.
The article should distinguish risk-based PSA screening and targeted evaluation from the use of PSA trends to monitor known prostate cancer. Neither result diagnoses or excludes prostate cancer by itself.
Ulta Lab Tests, LLC.
9237 E Via de Ventura, Suite 220
Scottsdale, AZ 85258
480-681-4081
(Toll Free: 800-714-0424)
